Phibro Animal Health Corp. Hits New 52-Week High of $42.80

Phibro Animal Health Corp. has reached a significant milestone by hitting a new 52-week high of USD 42.80 on October 24, 2025. This achievement underscores the company's robust performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 1,598 million.
Over the past year, Phibro has demonstrated impressive growth, with a remarkable 150.03% increase in stock value, significantly outperforming the S&P 500, which saw a gain of 16.9%. The company's financial metrics reflect strong fundamentals, including a price-to-earnings (P/E) ratio of 21.00 and a return on equity (ROE) of 18.91%. Additionally, Phibro boasts a solid dividend yield of 1.22% and a low debt-to-equity ratio of 2.28, indicating a stable financial position.

The company has consistently reported positive results, including a staggering 2190.43% growth in net profit as of June 25, and has maintained a high return on capital employed (ROCE) of 17.8%. With high institutional holdings at 100%, Phibro Animal Health Corp. continues to solidify its position as a reliable performer in the market.